Biofourmis

Biofourmis—a fast-growing global leader in digital therapeutics that powers personalized predictive care—discovers, develops and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and complement pharmacotherapy, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics product pipeline across multiple therapeutic areas—including heart failure, oncology, infectious disease (i.e., COVID-19), chronic pain, acute coronary syndrome and COPD.

88.3logo
logo
logo
logo
logo
logo
88.3
logo
NaN
logo
NaN
logo
NaN
logo
NaN
Links
logo
logologologo
Valuation
logo
$
Valuation
Funding
logo
$
$ 20.00 M
$ 463.07 M
Funding
$ 20.00 M
$ 463.07 M
Statistics
logo
NA
Action

Biofourmis—a fast-growing global leader in digital therapeutics that powers personalized predictive care—discovers, develops and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and complement pharmacotherapy, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics product pipeline across multiple therapeutic areas—including heart failure, oncology, infectious disease (i.e., COVID-19), chronic pain, acute coronary syndrome and COPD.

Overview
Last verified: 10/15/2022
Merck KGaAMerck KGaAMerck KGaAMerck KGaAMerck KGaA 
View All
logologologo
0and0